COVID-19 vaccine News
-
BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
By BioLingus AG
-
Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants
The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to create new vaccines at an unprecedented speed. Despite the success of current vaccines in ...
-
How to freeze-dry a potential COVID-19 vaccine
Things that are freeze-dried: Astronaut food. Emergency rations. And, just maybe, some future COVID-19 vaccines. Freeze-drying is a method for removing water from a product. First, you freeze the item you’re trying to dehydrate, causing any water in it to become ice. Then, you remove the ice through a process called sublimation, in which ice turns directly into vapor under low pressure. In ...
-
SpyBiotech featured in The Guardian Value of Vaccines supplement
SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments. "The COVID-19 vaccine uses SpyBiotech's unique protein "superglue" technology to display the SARS ...
-
Aerogen supports global vaccine equity and neonatal health with UNICEF
UNICEF Ireland welcomes two-year partnership with Galway-based Aerogen UNICEF and Aerogen have announced a two-year partnership in support of UNICEF’s work in the areas of global vaccine equity and the health of newborns. In 2021, Aerogen has committed €50,000 to go towards funding UNICEF’s delivery of 2 billion COVID-19 vaccines to the most vulnerable families, health workers ...
By Aerogen
-
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ ...
By Vaxxinit
-
Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of ...
-
Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the ...
-
AKCP Develops COVID-19 Vaccine Delivery Monitoring
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. The Pfizer vaccine at -70°C +/- 10°C whereas Moderna requires -20°C. Both can be transferred to standard medical refrigerators for short periods of time. The latest COVID-19 vaccine to be announced from AstraZeneca ...
By AKCP
-
Micron Biomedical Presents at the White House Summit on the Future of COVID-19 Vaccines
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
-
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. ...
By Novavax
-
Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose
? Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern ? MV-014-212 was built on the company’s AttenuBlock platform and is designed to be appropriately attenuated, genetically stable, and optimized to drive robust, broad, and durable immunity ? Data will be ...
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
IRVINE, Calif. – Oct. 4, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote address at the Advanced Therapies Congress & Expo in London, taking place October 5-6. Dr. Keirstead will speak at the following time and location: Keynote: Cell-based ...
-
ICMA and National League of Cities CEOs Encourage Trust in Health & Safety of COVID Vaccine
With the recent approval of a COVID-19 vaccine, there is great hope that there will soon be an end to what is arguably the most painful and deadliest public health crisis in our country’s history. While a mass vaccination program, now underway, will bring healing to a nation that has witnessed more than 300,000 COVID deaths, medical authorities tell us that we are still months away from ...
-
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical ...
-
Sad, But True: Beware Counterfeits in the Time of COVID-19
It’s nothing short of miraculous that COVID-19 tests, N95 respirators and SARS-CoV2 vaccines were made available so quickly. But, sadly we are compelled to ask…are they real or counterfeit? Since December of 2019, herculean efforts have resulted in amazing strides in warp speed towards development, supply and distribution of disease-confirming analytical tools, disease-mitigating ...
-
Covid-19 Vaccine Developed By Ub Startup Enters Human Trials
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. The vaccine candidate, called EuCorVac-19, was jointly developed by Buffalo biotech company POP Biotechnologies and South Korean biotech company EuBiologics. POP Biotechnologies was founded in 2015 by former UB students Kevin Carter and Jonathan Smyth and UB ...
-
Oramed Issues Annual Message to Shareholders
Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and partnerships Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical ...
-
Aerogen leading the way for inhaled COVID-19 vaccine delivery
Company’s aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of patient-generated infectious aerosol during ventilation2–7. Hospitals around the ...
By Aerogen
-
HHS Announces $22 Billion in Funding to Support Expanded Testing, Vaccination Distribution
The Department of Health and Human Services (HHS) today announced two upcoming actions by the Centers for Disease Control and Prevention (CDC) to provide more than $22 billion in funding to states, localities, and territories in support of the nation’s response to the COVID-19 pandemic, as directed by the Coronavirus Response and Relief Supplemental Appropriations Act. Funding will ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you